Neuroscientific Biopharmaceuticals Ltd (AU:NSB) — Market Cap & Net Worth
Market Cap & Net Worth: Neuroscientific Biopharmaceuticals Ltd (NSB)
Neuroscientific Biopharmaceuticals Ltd (AU:NSB) has a market capitalization of $14.59 Million (AU$20.62 Million) as of September 26, 2026. Listed on the AU stock exchange, this Australia-based company holds position #26147 globally and #1171 in its home market, demonstrating a -4.62% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Neuroscientific Biopharmaceuticals Ltd's stock price AU$0.06 by its total outstanding shares 332575706 (332.58 Million). Also see NSB current and non-current assets for a full breakdown of the balance sheet.
Neuroscientific Biopharmaceuticals Ltd Market Cap History: 2018 to 2026
Neuroscientific Biopharmaceuticals Ltd's market capitalization history from 2018 to 2026. Data shows change from $30.59 Million to $14.59 Million (-14.60% CAGR). Also see cash efficiency ratio of Neuroscientific Biopharmaceuticals Ltd for how efficiently the company converts equity into cash flow.
Neuroscientific Biopharmaceuticals Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Neuroscientific Biopharmaceuticals Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check NSB share price today for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
155.86x
Neuroscientific Biopharmaceuticals Ltd's market cap is 155.86 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2018 | $30.59 Million | $28.88K | -$931.42K | 1059.41x | N/A |
| 2019 | $44.71 Million | $33.85K | -$1.66 Million | 1320.88x | N/A |
| 2020 | $58.83 Million | $76.27K | -$2.87 Million | 771.33x | N/A |
| 2021 | $78.83 Million | $958.77K | -$3.18 Million | 82.22x | N/A |
| 2022 | $29.41 Million | $68.45K | -$10.44 Million | 429.73x | N/A |
| 2023 | $10.35 Million | $4.95 Million | -$1.07 Million | 2.09x | N/A |
| 2024 | $7.77 Million | $2.21 Million | $324.21K | 3.51x | 23.95x |
| 2025 | $25.89 Million | $166.08K | -$1.85 Million | 155.86x | N/A |
Competitor Companies of NSB by Market Capitalization
Companies near Neuroscientific Biopharmaceuticals Ltd in the global market cap rankings as of September 26, 2026. Review Neuroscientific Biopharmaceuticals Ltd (NSB) tangible equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Neuroscientific Biopharmaceuticals Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #185 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #339 globally with a market cap of $79.70 Billion USD.
- CSL Ltd (AU:CSL): Ranked #453 globally with a market cap of $60.74 Billion USD ( AU$85.85 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #507 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #185 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $526.19 |
| #339 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $79.70 Billion | $788.04 |
| #453 | CSL Ltd | AU:CSL | $60.74 Billion | AU$176.95 |
| #507 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $198.88 |
Neuroscientific Biopharmaceuticals Ltd Historical Marketcap From 2018 to 2026
Between 2018 and today, Neuroscientific Biopharmaceuticals Ltd's market cap moved from $30.59 Million to $ 14.59 Million, with a yearly change of -14.60%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | AU$14.59 Million | -43.64% |
| 2025 | AU$25.89 Million | +233.33% |
| 2024 | AU$7.77 Million | -25.00% |
| 2023 | AU$10.35 Million | -64.80% |
| 2022 | AU$29.41 Million | -62.69% |
| 2021 | AU$78.83 Million | +34.00% |
| 2020 | AU$58.83 Million | +31.58% |
| 2019 | AU$44.71 Million | +46.15% |
| 2018 | AU$30.59 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 26th, 2026 the market cap of Neuroscientific Biopharmaceuticals Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $14.59 Million USD |
| MoneyControl | $14.59 Million USD |
| MarketWatch | $14.59 Million USD |
| marketcap.company | $14.59 Million USD |
| Reuters | $14.59 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Neuroscientific Biopharmaceuticals Ltd
NeuroScientific Biopharmaceuticals Limited engages in the research and development of biomedical products targeting neurodegenerative conditions. Its lead product is the EmtinB drug for the treatment of optic nerve diseases, such as glaucoma. The company also develops StemSmart platform technology to treat inflammatory immune disorders. NeuroScientific Biopharmaceuticals Limited was incorporated … Read more